Scholarlink

<p>Male breast cancer is a rare disease and accounts for ∼1% of all cancers in men. Men often present in an advanced stage of the disease. This is a case series analysis. The objective was to look for tumor characteristics, histological subtypes, and treatment modalities in male breast cancer patients from January 2018 to December 2023 at a tertiary care center in northeast India. A total of 30 patients were included in the study. The median age at diagnosis was 59&#xa0;years. The most common location was retro areolar. The most common presentation was a painless lump. The median clinical tumor size was 3.5&#xa0;cm. The most common stage at presentation was stage II. Invasive ductal carcinoma of no special type grade II was the most common histological subtype. The most common molecular subtypes were luminal A (76%), luminal B (20%), and triple-negative breast cancer (TNBC) in 4%. Upfront surgery was planned in 82.6% of patients, of which 74% of patients underwent modified radical mastectomy (MRM), while breast conservation surgery (BCS) was done in 8% of patients. Neoadjuvant chemotherapy (NACT) was planned in 4 patients (17%). Only 59% of patients were fully compliant with the treatment modalities. Disease relapse (locoregional and distant metastasis) was found in 34% of patients. The median time for disease relapse was 32&#xa0;months. Mortality was found in 23% of patients. Three-year overall survival (OS) with a 95% confidence interval was 63% (39.4–86.5). The median OS was 42&#xa0;months with 95% CI (18.4–65.5). The majority of male breast cancer presented as invasive ductal carcinoma, hormone receptor-positive, and early stage of presentation. The stage of disease and hormone receptor status were the main prognostic factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Male Breast Cancer: Clinicopathological Characteristics of the Patients Treated in a Tertiary Care Centre in Northeast India

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月26日

查看全文
  • Arshnoor Kaur,
  • Pompi D. Buragohain,
  • Abhijit Talukdar,
  • Partha S. Roy,
  • Zaveri Mohinta,
  • Mohit Malhotra

摘要

Male breast cancer is a rare disease and accounts for ∼1% of all cancers in men. Men often present in an advanced stage of the disease. This is a case series analysis. The objective was to look for tumor characteristics, histological subtypes, and treatment modalities in male breast cancer patients from January 2018 to December 2023 at a tertiary care center in northeast India. A total of 30 patients were included in the study. The median age at diagnosis was 59 years. The most common location was retro areolar. The most common presentation was a painless lump. The median clinical tumor size was 3.5 cm. The most common stage at presentation was stage II. Invasive ductal carcinoma of no special type grade II was the most common histological subtype. The most common molecular subtypes were luminal A (76%), luminal B (20%), and triple-negative breast cancer (TNBC) in 4%. Upfront surgery was planned in 82.6% of patients, of which 74% of patients underwent modified radical mastectomy (MRM), while breast conservation surgery (BCS) was done in 8% of patients. Neoadjuvant chemotherapy (NACT) was planned in 4 patients (17%). Only 59% of patients were fully compliant with the treatment modalities. Disease relapse (locoregional and distant metastasis) was found in 34% of patients. The median time for disease relapse was 32 months. Mortality was found in 23% of patients. Three-year overall survival (OS) with a 95% confidence interval was 63% (39.4–86.5). The median OS was 42 months with 95% CI (18.4–65.5). The majority of male breast cancer presented as invasive ductal carcinoma, hormone receptor-positive, and early stage of presentation. The stage of disease and hormone receptor status were the main prognostic factors.